Life
Novo's Subscription Model and Its Implications for Pharma-Telehealth Collaborations
Novo's recent subscription model raises critical questions regarding the integration of pharmaceutical companies with telehealth services, particularly in light of regulatory delays.
Editorial Staff
1 min read
Novo's introduction of a subscription model for its products has sparked discussions about the potential impacts on partnerships between pharmaceutical companies and telehealth platforms.
This model could influence how medications are accessed and managed through telehealth services, particularly as the industry navigates evolving regulatory environments.
The delayed FDA decision for Orca Bio further complicates the landscape, highlighting the need for clear frameworks that govern the intersection of pharmaceuticals and telehealth.